ERBB2 and breast carcinoma: All of this resulted in T-DXd receiving accelerated FDA approval in 2019 for the treatment of adult patients with inoperable or metastatic HER2-positive breast cancer or metastatic breast cancer who had previously received two or more anti-HER2-based treatment regimens.